ABCG2 and cancer: HIF-1α plays a role in therapy resistance via various mechanisms, notably by activating multidrug resistance (MDR) proteins, such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), which facilitate the efflux of chemotherapeutic agents from cancer cells [28].